ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
April 11 2018 - 4:05PM
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced the presentation
of positive safety, efficacy and quality of life results from the
Company’s successfully completed Phase II CLEAR and CLASSIC
clinical trials of avacopan in the treatment of anti-neutrophil
cytoplasmic auto-antibody-associated vasculitis (ANCA Vasculitis).
The findings are being presented during the 2018 Spring Clinical
Meetings of the National Kidney Foundation (NKF), being held April
10-14, 2018 in Austin, Texas.
Presentation Information:
Abstract Title: C5aR Inhibitor Avacopan in Anti-Neutrophil
Cytoplasmic Autoantibody (ANCA) Vasculitis: Phase II Outcomes of
Safety, Renal Parameters, and Quality of Life
Abstract Number: 266
Authors: T. Schall, A. Potarca, J. Hillson, P. Bekker (for CLEAR
and CLASSIC Study Teams) ChemoCentryx, Mountain View, CA
Poster Presentation Date & Time: Wednesday, April 11, at 6pm
CT to Friday, April 13, at 10am CT
Location: Austin Convention Center, Austin, TX
About Avacopan
Avacopan is an orally-administered small molecule that is a
selective inhibitor of the terminal effector and neutrophil
chemoattractant complement C5a receptor, or C5aR. It allows
tempering of ANCA responses and thereby to prevent both complement
C5a activation while leaving other host defense mechanisms (such as
the membrane attack complex, being distinct from C5b) of the immune
system unaffected. Avacopan is in phase III development for the
treatment of anti-neutrophil cytoplasmic auto-antibody-associated
vasculitis (ANCA vasculitis). In clinical studies to date, avacopan
was shown to be safe, well tolerated and provided effective control
of the disease while successfully allowing elimination of high-dose
steroids, part of the standard of care for patients with ANCA
vasculitis. Avacopan is also being developed in patients with C3
glomerulopathy (C3G), hidradenitis suppurativa (HS) and in atypical
hemolytic uremic syndrome (aHUS). In C3G, avacopan targets the C5a
receptor, blocking the effects of C5a which contributes to the
inflammatory hypercellularity in the glomeruli, a main feature of
C3G. The U.S. Food and Drug Administration has granted avacopan
orphan-drug designation for ANCA vasculitis, C3G, and aHUS. The
European Commission has granted orphan medicinal product
designation for avacopan for the treatment of two forms of ANCA
vasculitis: microscopic polyangiitis and granulomatosis with
polyangiitis (formerly known as Wegener's granulomatosis), as well
as for C3G. Avacopan was also granted access to the European
Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative,
which supports accelerated assessment of investigational therapies
addressing unmet medical need.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications targeted at inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and chemoattractant
systems to discover, develop and commercialize orally-administered
therapies. ChemoCentryx is currently focusing on its late stage
drug candidates for patients with rare kidney diseases, avacopan
(CCX168) and CCX140.
Avacopan is an orally-administered small molecule that is a
selective inhibitor of the complement C5a receptor, or C5aR.
Avacopan is in Phase III development for the treatment of
anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
(ANCA Vasculitis). In clinical studies to date, avacopan was shown
to be safe, well tolerated and provided effective control of the
disease while allowing elimination of high-dose steroids, part of
the current standard of care. Avacopan is also being developed in
patients with C3 glomerulopathy (C3G), hidradenitis suppurativa
(HS) and atypical hemolytic uremic syndrome (aHUS).
The Company's other late stage drug candidate is CCX140, an
inhibitor of the chemokine receptor known as CCR2, which is
currently being developed for patients with focal segmental
glomerulosclerosis (FSGS), a debilitating kidney disease.
ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides
Vifor Pharma with exclusive rights to commercialize avacopan and
CCX140 in markets outside of the U.S. and China.
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other Inflammatory and autoimmune
diseases and in cancer.
Forward-Looking Statements
ChemoCentryx cautions that statements included in this press
release that are not a description of historical facts are
forward-looking statements. Words such as "may," "could," "will,"
"would," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "intend," "predict," "seek," "contemplate,"
"potential," "continue" or "project" or the negative of these terms
or other comparable terminology are intended to identify
forward-looking statements. These statements include the
Company's statements whether avacopan (CCX168) will be shown to be
safe and effective in the treatment of ANCA vasculitis and other
rare diseases. The inclusion of forward-looking statements should
not be regarded as a representation by ChemoCentryx that any of its
plans will be achieved. Actual results may differ from those set
forth in this release due to the risks and uncertainties inherent
in the ChemoCentryx business and other risks described in the
Company's filings with the Securities and Exchange Commission
("SEC"). Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and ChemoCentryx undertakes no obligation to revise or
update this news release to reflect events or circumstances after
the date hereof. Further information regarding these and other
risks is included under the heading "Risk Factors" in
ChemoCentryx's periodic reports filed with the SEC, including
ChemoCentryx's Annual Report on Form 10-K filed with the SEC on
March 12, 2018 and its other reports which are available from the
SEC's website (www.sec.gov) and on ChemoCentryx's website
(www.chemocentryx.com) under the heading "Investors." All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.
Source: ChemoCentryx, Inc.
CCXI-G
Contacts:
Susan M.
Kanaya
Executive Vice President, Chief Financial and Administrative
Officer
investor@chemocentryx.com
Media:Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Burns McClellan, Inc. Steve
Klass212.213.0006
sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024